Advances in Immunotherapy and the TGF-β Resistance Pathway in Metastatic Bladder Cancer
Bladder cancer accounts for nearly 200,000 deaths worldwide yearly. Urothelial carcinoma (UC) accounts for nearly 90% of cases of bladder cancer. Cisplatin-based chemotherapy has remained the mainstay of treatment in the first-line setting for locally advanced or metastatic UC. More recently, the tr...
Enregistré dans:
Auteurs principaux: | David J. Benjamin, Yung Lyou |
---|---|
Format: | article |
Langue: | EN |
Publié: |
MDPI AG
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/26625f45f9874fcfa537b6f572bfa57c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
TGF-β Signaling and Resistance to Cancer Therapy
par: Maoduo Zhang, et autres
Publié: (2021) -
A review on the evolution of immunotherapy in bladder carcinoma
par: Milena Gulinac, et autres
Publié: (2020) -
CRTAC1 (Cartilage acidic protein 1) inhibits cell proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) process in bladder cancer by downregulating Yin Yang 1 (YY1) to inactivate the TGF-β pathway
par: Jianghua Yang, et autres
Publié: (2021) -
Lymphoepithelioma-Like Carcinoma of Urinary Bladder with Diagnostic Dilemma: Case Report of A Rare Variant of Urothelial Carcinoma
par: Swati Saini, et autres
Publié: (2021) -
GPR37 promotes the malignancy of lung adenocarcinoma via TGF-β/Smad pathway
par: Wang Jian, et autres
Publié: (2020)